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Background: Hyperammonemia is a life-threatening event that can occur at any age. If treated, 
the early symptoms in all age groups could be reversible. If untreated, hyperammonemia could 
be toxic and cause irreversible brain damage to the developing brain.
Objective: There are major challenges that worsen the outcome of hyperammonemic individuals in 
the Middle East. These include: lack of awareness among emergency department physicians about 
proper management of hyperammonemia, strained communication between physicians at primary, 
secondary, and tertiary hospitals, and shortage of the medications used in the acute management 
of hyperammonemia. Therefore, the urge to develop regional guidelines is extremely obvious.
Method: We searched PubMed and Embase databases to include published materials from 
2011 to 2014 that were not covered by the European guidelines, which was published in 2012. 
We followed the process of a Delphi conference and involved one preliminary meeting and 
two follow-up meetings with email exchanges between the Middle East Hyperammonemia and 
Urea Cycle Disorders Scientific Group regarding each draft of the manuscript.
Results and discussion: We have developed consensus guidelines based on the highest 
available level of evidence. The aim of these guidelines is to homogenize and harmonize the 
treatment protocols used for patients with acute hyperammonemia, and to provide a resource to 
not only metabolic physicians, but also physicians who may come in contact with individuals 
with acute hyperammonemia.
Conclusion: These suggested guidelines aim to ease the challenges faced by physicians dealing 
with acute hyperammonemia in the region. In addition, guidelines have demonstrated useful col-
laboration between experts in the region, and provides information that will hopefully improve 
the outcomes of patients with acute hyperammonemia.
Keywords: hyperammonemia, inborn errors of metabolism, urea cycle, acute management, 
ammonia, Middle East
Introduction
Acute hyperammonemia is defined as elevated plasma ammonia levels associated 
with muscular hypotonia, seizures, vomiting, and impaired consciousness.1 The 
clinical features are heterogeneous depending on the age of the patient and on the 
type and severity of the underlying cause.2 The early symptoms in all age groups 
are loss of appetite and vomiting, which could be reversible if recognized and 
treated early. In newborns, common early symptoms are poor feeding, vomiting, 
lethargy, hyperventilation resulting often in respiratory alkalosis, and irritabil-
ity that rapidly progresses to seizures, deep coma, and even death if not urgently 
treated. In infants, vomiting mimics pyloric stenosis, cow milk intolerance, or 
gastroenteritis. In older children and adults, vomiting, protein aversion, ataxia, 
confusion, disorientation, hallucinations, or abnormal behavior point to central 
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nervous system or psychiatric disorders.2 If untreated, 
severe hyperammonemia will be neurotoxic and will cause 
irreversible brain damage both to the developing as well as 
to the mature brain.1–5 Hyperammonemic encephalopathy 
is associated with high mortality rates.6,7 The total duration 
of a hyperammonemic coma and the extent of hyperam-
monemia are the most relevant prognostic factors and 
are negatively correlated with the patient’s neurological 
outcome.6–8 Therefore, prompt identification and treatment 
of hyperammonemia are vital to optimize the outcome.
In the Middle East, the prevalence of urea cycle disor-
ders and organic acidemias, which are the major causes of 
hyperammonemia, is probably higher than in other parts of 
the world.9–12 This is most likely due to the high rate of con-
sanguinity leading to increased autosomal recessive disorders 
in the region.13–16 In addition to the high prevalence, there 
are several major challenges that must be considered as risk 
factors for the outcome of hyperammonemic individuals in 
the Middle East. These include lack of awareness of health 
care professionals about prompt diagnosis and adequate 
management of hyperammonemia, strained communication 
between physicians at primary, secondary, and tertiary hospi-
tals, and lack of knowledge and availability of the diagnostic 
tools and medications required in the acute management 
of hyperammonemia. Finally, the recognition of late onset 
and milder cases diagnosed in adulthood would require the 
particular alertness among internists and adult intensive care 
units, a goal certainly not yet everywhere achieved. Based on 
these considerations, we regard the development of regional 
guidelines for the acute management of hyperammonemia 
as urgent and a chance to improve the patients’ outcome in 
the Middle East. In this article, therefore, we have developed 
consensus guidelines that in particular address the unique 
situation in the Middle East and have based them on the high-
est available level of evidence. The aim of these guidelines is 
to homogenize and harmonize the various regional treatment 
protocols currently used for patients with acute hyperam-
monemia, and to provide a resource for metabolic specialists 
and likewise for physicians who may come in contact with 
individuals with acute hyperammonemia.
Method
We have based our guidelines on the European guidelines,17 
published in 2012, which followed a strict methodological 
protocol. To include all relevant recent information, we 
searched PubMed and Embase databases to include pub-
lished materials from 2011 to 2014 that were not covered by 
the European guidelines.1,6,18–38 Development of the present 
guidelines followed the process of a Delphi conference 
and involved one preliminary meeting and two follow-up 
meetings with email exchanges between the Middle East 
Hyperammonemia and Urea Cycle Disorders Scientific 
Group regarding each draft of the manuscript. The Middle 
East Hyperammonemia and Urea Cycle Disorders Scientific 
Group include an expert panel of metabolic specialists from 
countries in the Middle East as well as renowned international 
advisors. The process of guideline development followed 
Grading of Recommendations Assessment, Development, 
and Evaluation methodology of classifying the evidence.39,40 
Although these guidelines are developed with highest 
accuracy, such guidelines should be considered as recom-
mendations that aim at guiding physicians, but should not be 
considered as a protocol that is blindly followed. In particu-
lar, as each patient is an individual and each situation may 
vary from what is described here, all medical decisions must 
be carefully made on an individual basis.
Evidence levels were classified in accordance with the 
Grading of Recommendations Assessment, Development, 
and Evaluation methodology.39–42
Results and discussion
The first part of the results and discussion will focus on 
identifying unknown patients at risk for hyperammonemia. 
We regard an earlier identification of affected patients 
with high index of suspicion as a key to overall improved 
prognosis. The second part describes recommendations for 
the acute management of hyperammonemia and is divided 
into several sections according to practical considerations. 
Finally, other issues related to management and prognosis 
of hyperammonemia will be discussed. Embedded in the 
discussion are some answers to valid questions that may 
rise during the management of hyperammonemia in an 
emergency setting.
Although these guidelines are built upon previously 
published guidelines, the novelty of these guidelines is the 
focus on answers to many practical questions that were not 
discussed in depth in the previously published materials.17,43 
Examples for practical aspects are: the meaning and definition 
of a high caloric intake, the normal ammonia levels according 
to the age, the amount of potassium in intravenous (IV) fluids 
when hyperammonemia scavengers are used. Additionally, 
the responsible person for insertion of the line(s) for dialysis, 
and the dosage of insulin if it is used during initial manage-
ment of hyperammonemia are discussed. The protocol and 
suggested guidelines are summarized in Tables 1 and 2, 
respectively.
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Table 1 Protocol for acute management of primary hyperammonemia based on ammonia level
Ammonia level (µmol/L) Undiagnosed case Diagnosed case
above upper limit of normal •	 stop protein intake
•	 give iV glucose at an appropriate dosage to prevent 
catabolism ± insulin
same as Undiagnosed case
.100 but ,250 (in neonate 
.150 but ,250)
•	 same as above
•	 start drug treatment with nitrogen scavengers (l-arginine 
and aMMOnUl®)
•	 start carnitine, biotin, vitamin B12
•	 start Carbaglu®
•	 start lipid iV 2–3 g/kg to give higher calories
start medications and nitrogen scavengers according 
to the protocol of each disorder
250–500 •	 same as above
•	 Prepare for CRRT
•	 Begin CRRT, if no rapid drop of ammonia within 3–6 hours 
same as Undiagnosed case
.500 start CRRT with above measure
Abbreviations: iV, intravenous; CRRT, continuous renal replacement therapy.
Table 2 summary of protocol of acute management of hyperammonemia
•	 Basic life support (CaB)
•	 stop all source of protein both enteral and parenteral nutrition for a maximum of 24–48 hours
•	 Check glucose level (glucoCheck)
•	 insert an iV line (central and peripheral) and take blood for ammonia (nh3), blood gases, Chem 1, and CBC, blood C/s (peripheral and central if 
patient has central line). liver transaminases, Ca, alkaline phosphatase as sTaT order
•	 ammonia should be taken with precaution (without tourniquet, transported in ice water to the laboratory, separated within 30 minutes 
of collection, and analyzed immediately)
•	 start 1.5 to double maintenance iVF as D10%, 0.45 ns + KCl 30 meq/l until serum K result is available, then adjust accordingly
•	 Call the pharmacy to prepare the medications and intralipid (see dosages in Tables 1 and 4)
•	 Call biochemical geneticist (metabolic) on call
•	 Consider starting insulin if hyperglycemia develops (glucose .10 mmol/l) at dose of 0.05–0.1 unit/kg/h and titrate up until blood glucose controlled 
(keep glucoCheck 6.5–10 mmol/l). Total glucose requirements (mg/kg/min) depends on the age (0–1 year: 8–10, 1–3 years: 7–8, 4–6 years: 6–7, 
7–12 years: 5–6, adolescent: 4–5, adults: 3–4)
•	 if ammonia .100 µmol/l in infants, children, and adults; and .150 µmol/l in neonates start loading dose of combined sodium benzoate 
and sodium phenylacetate (aMMOnUl®) and arginine (see Tables 1 and 4)
•	 start iV intralipid 20% 2–3 g/kg/day to give additional calories (if fatty acid oxidation defects are excluded)
•	 if the patient is on combined sodium benzoate and phenylacetate (aMMOnUl®) or arginine give KCl 40 meq/l because they cause 
hyperchloremic hypokalemic metabolic acidosis. KCl can be given through peripheral line up to 60 meq/l; rate must not exceed 0.125 meq/kg/h
•	 start dialysis if ammonia .300–500 µmol/l in neonates and children and there is no response to the medical treatment within 4 hours. Consult 
iCU and nephrology team if you anticipate starting dialysis in the next few hours
•	 Reloading has to be done carefully, in particular during the first 24 hours, as cumulative doses of .750 mg/kg/24 h of combined sodium benzoate 
and phenylacetate (aMMOnUl) have been shown to be associated with development of toxicity (vomiting, lethargy). Reloading only in neonates 
with severe disorders or those who are undergoing dialysis, and should be spaced at least 6 hours 
•	 in an undiagnosed acute case also start N-carbamylglutamate (Carbaglu®). it only exists as an enteral form, so it is generally given by ng tube. 
Give 100 mg/kg once followed by 50 mg/kg q 6 h. Once it is clear that the patient does not have NAGS or CPS1 deficiency or organic acidemias, it 
should be stopped
•	 in an undiagnosed acute case, start levocarnitine iV/PO 100 mg/kg/day divided q 6-8 h, hydroxycobalamin 1 mg iM/iV/PO, and biotin 10 mg iV/PO
•	 give glucose polymers, or protein-free formulas (eg, Pro-phree, Polycose, or Maxijul) through PO/ng as tolerated to give additional calories
•	 Do not decrease dextrose rate or amount and do not stop calorie delivery in the acute stage for any reason (eg, medications, fluid bolus, or 
hyperglycemia) as this can precipitate hypoglycemia and catabolism, which will further worsen the patient’s condition
•	 Call metabolic dietitian on call
•	 if patient has a known diagnosis, do not stop other oral chronic medications (in case of vomiting, convert to iV forms if available)
•	 antibiotics may be started if there is any evidence of sepsis. ammonia, electrolyte, and blood gases analysis need to be done at regular intervals during 
this acceleration of management stage. The frequency is dictated by the patient’s condition and the speed at which results can be obtained
•	 Protein should be reintroduced within 24–48 hours of initiation of therapy even if the patient is on dialysis
Abbreviations: CBC, complete blood count; CaB, circulation, airway, breathing; Chem 1, na, K, Cl, creatinine; C/s, culture and sensitivity; Ca, calcium; nags, 
N-acetylglutamate synthase; CPS1, carbamoyl phosphate synthetase 1; IVF, intravenous fluid; D10, dextrose 10%; NS, normal saline; NG, nasogastric; h, hours; IM, 
intramuscular; iV, intravenous; PO, peroral.
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identifying unknown patients at risk for 
hyperammonemia
When to order ammonia analysis?
Patients from all age groups who present with encephal-
opathy of unknown etiology should undergo measurements 
of plasma ammonia (NH
3
).17 The signs and symptoms of 
hyperammonemia can vary according to age, but are nonspe-
cific in all age groups. In neonates, lethargy, poor feeding, and 
vomiting are frequent; it may progress to central hyperven-
tilation, seizures, coma, and death if left untreated. In older 
children, symptoms include unexplained change in conscious-
ness, unexplained or unusual neurological or psychiatric ill-
ness, and acute liver failure. Chronically, hyperammonemia 
can present as recurrent vomiting, headache, ataxia, strange 
behavior, especially if it occurs episodically, developmental 
delay, and aversion to protein. It is strongly recommended 
to consider ammonia measurement in all encephalopathic 
patients, especially in newborns who require a septic screen 
and are sick looking at the same time.1,2,17,23,25 Hospitals may 
also decide to install an automatic red flag as warning for 
certain clinical circumstances as recently suggested.23
statement #1: strong recommendation, low quality 
evidence (1C)
Any individual at any age who presents with any of the fol-
lowing symptoms should undergo prompt plasma ammonia 
determination:
•	 Acute unexplained encephalopathy
•	 Acute neurological illness
•	 Suspected sepsis in a newborn
•	 Developmental delay of unknown cause
•	 Recurrent vomiting
•	 Acute liver failure, elevated transaminases of unknown 
cause
•	 Ataxia
•	 Headache, especially if episodic in women
•	 Coma or stupor
•	 Psychiatric symptoms
•	 Aversion to protein.
initial management when 
hyperammonemia is suspected
Once hyperammonemia is suspected, the patient should be 
managed in a hospital with access to basic metabolic tests, 
first-line hyperammonemia medications, dialysis facilities, 
and metabolic specialists. If any of these elements are not 
available, the patient should be transferred without delay to a 
specialist center after stabilization according to basic life sup-
port (circulation, airway, and breathing), addressing vital signs 
as with any critically ill patient and including blood glucose 
monitoring.44 In addition, the following should be done:
1. Insert IV lines, if possible as a central venous access. 
If this cannot be achieved, an intraosseous access could 
be an alternative.
2. Maintain airway: intubate and ventilate if necessary.
3. Adequate rehydration using minimum of dextrose 10% 
glucose and high calorie intake, maintain normal blood 
pressure, and add vasopressors if necessary.
4. Take blood and urine samples as outlined in Table 3.
What ammonia levels require immediate action?
The normal ammonia level varies based on the patient’s age. 
There is no scientifically sound consensus about the upper 
normal limit for each age group. However, in general hyper-
ammonemia is considered if plasma ammonia is .50 µmol/L 
in infants, children, and adults and .100 µmol/L in 
newborns.25,45 Other authors have described the normal refer-
ence range as follows: up to 7 days: 94 µmol/L, 8–30 days: 
80 µmol/L, 1 month–15 years: 48 µmol/L, and .15 years: 
26 µmol/L.46 It should be highlighted that the values 
presented here should be considered as decision limits; the 
normal reference ranges of individual laboratories should be 
used for clinical interpretation. An alert system for nurses and 
clinicians should be active in the lab in case ammonia is above 
the reference range and this must be reported immediately to 
the health care professional in charge of the patient.
Table 3 laboratory testing that should be done in any patient 
suspected of having hyperammonemia
ammonia
glucose
Venous/arterial blood gas
electrolytes (including calcium)
anion gap
Blood urea nitrogen
Creatinine
liver transaminases
Bilirubin
albumin
alkaline phosphatase
lactate
lipase (if symptoms indicate)
Blood culture
Complete blood count
Acylcarnitine profile (tandem mass spectrometry), total and free carnitine
Plasma amino acids
save a blood sample for Dna banking and Dna testing (if genotype is 
not known)
Urine ketones (healthy infants should not have any)
Urine organic acids (obtained within 2 hours of presentation by any 
method of collection)
Urine for orotic acid
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statement #2: strong recommendation, low quality 
evidence (1C)
The normal reference ranges of individual laboratories should 
be used for clinical interpretation. In general, hyperammonemia 
requires further action, if plasma ammonia is .50 µmol/L in 
infants, children, and adults and .100 µmol/L in neonates. The 
given limits of plasma ammonia are decision limits (Table 1).
What precaution must be taken for 
testing of ammonia?
False-positive hyperammonemia is not uncommon; therefore, 
several precautions should be taken into consideration when 
collecting blood samples to measure ammonia:
•	 A free-flowing venous (or arterial) blood sample without 
tourniquet should be collected into a tube containing an 
anticoagulant (eg, lithium or heparin).
•	 The sample should be placed in ice water, transported to 
the laboratory, and analyzed immediately. Results should 
be available within 60 minutes of drawing the samples.
statement #3: strong recommendation, moderate 
quality evidence (1B)
Ammonia should be measured in an emergency setting with 
results available in 60 minutes.
statement #4: strong recommendation, low quality 
evidence (1C)
It is crucial to take blood for plasma amino acids and urine for 
organic acids and orotic acid before starting the treatment; how-
ever, urine sampling must not delay start of treatment.
What are the key elements of the initial 
management once hyperammonemia is 
identified?
Reversal of catabolism
a. Stop all sources of protein temporarily (for a maximum 
of 24–48 h).
b. Call the pharmacy to prepare the medications and glucose/
lipid infusions (see dosages in Table 4).
c. Check blood glucose regularly (GlucoCheck).
d. Start high caloric intake in form of IV dextrose 10%, or 
higher if appropriate, at the rate of 1.5 times to double 
of maintenance requirements, with age-dependent glu-
cose requirement (in mg/kg/min for 0–1 years: 8–10, 
1–3 years: 7–8, 4–6 years: 6–7, 7–12 years: 5–6, adoles-
cents: 4–5, adults: 3–4).47
e. If fatty acid oxidation defects are excluded, intralipid infu-
sions should be started at 2–3 g/kg/day to give additional 
calories.17,48
What do we mean by high caloric intake?
It means covering at least 110% of the recommended daily 
allowance in order to shut down endogenous protein break-
age (recommended daily allowance: for newborn and infant: 
110–120 kcal/kg/day, for 1–3 years: 100 kcal/kg/day, for 
4–6 years: 90 kcal/kg/day, for 7–10 years: 70 kcal/kg/day, 
for 11–14 years: 50–55 kcal/kg/day).47
statement #5: strong recommendation, low quality 
evidence (1C)
High index and early clinical suspicion as well as prompt 
diagnosis of hyperammonemia are vital to have a good out-
come. The treatment of hyperammonemia should be started 
without delay unless a decision for withdrawal of treatment 
and for palliative care is made.
What drugs are used to treat hyperammonemia?
Sodium benzoate and sodium phenylacetate are ammonia 
scavengers that bypass the urea cycle by conjugation of 
benzoate with glycine to generate hippurate, and of phenyl-
acetate with glutamine to generate phenylacetylglutamine, 
which are then excreted in urine. l-Arginine is a metabolite 
within the urea cycle and can help the urea cycle to run again 
if it is interrupted due to arginine deficiency resulting from 
a block within the urea cycle. Carbaglu® (N-carbamyl-l-
glutamate) can replace N-acetylglutamate as an activator of 
mitochondrial carbamoyl phosphate synthetase 1, the first 
enzyme of the urea cycle.17,49,50 The dosages of medications, 
mechanism of action, route, and side effects are summarized 
in Table 4.
Dialysis
What is the indication of dialysis?
neonates and children
Continuous venovenous hemodiafiltration should be started in 
neonates and children who have ammonia levels of .500 µmol/L 
or even at lower levels if there has been an inadequate response 
to medical management after 4 hours, which is the estimated 
time for preparing dialysis, including vascular access.51
statement #6: strong recommendation, low quality 
evidence (1C)
Dialysis is indicated in neonates and children with ammonia 
levels 300–500 µmol/L. Dialysis should be strongly consid-
ered in neonates and children with ammonia .500 µmol/L or 
when there is no response to the treatment. Consult intensive 
care unit and nephrology team, if you anticipate starting 
dialysis in the next few hours.
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adults
In adults, hemodialysis (HD) or continuous renal replace-
ment therapy (CRRT) in the form of continuous venovenous 
hemofiltration is the first-line therapy in case of acute 
hyperammonemia. Dialysis should be started as soon as 
possible when ammonia exceeds 200 µmol/L.17
statement #7: strong recommendation, low quality 
evidence (1C)
Dialysis is the first-line treatment in acute hyperammonemia 
decompensations in adults.
What is the method of choice for dialysis?
Dialysis choices usually include HD and CRRT. Alterna-
tively, but only in centers that lack the ability or expertise 
to perform extracorporeal therapy, peritoneal dialysis (PD) 
can be utilized. However, PD clears ammonia at a lower 
rate than hemodialysis modalities. HD is intermittent and 
gives highest ammonia clearance.18 However, in neonates, 
HD is difficult to perform due to technical challenges and 
a high risk of complications, for example, concerning the 
maintenance of an adequate blood pressure. Therefore, 
CRRT including continuous venovenous hemofiltration or 
continuous venovenous hemodiafiltration is the preferred 
method.17,18,52 It is very important to emphasize that at this 
stage, fast action is required to prevent brain injury; there-
fore, the line for dialysis should be inserted immediately. 
Every place should develop its own protocol for who should 
insert the dialysis line depending on the local resources. 
The catheter of dialysis can be removed after the plasma 
ammonia level has been stable in the normal range for at 
least a day. However, keeping the catheter in place should 
be balanced with the risk of maintaining the patient in an 
anticoagulated state.
Exchange transfusions should be avoided.17 Ammonia 
scavenger therapy needs to be continued during dialysis.
statement #8: strong recommendation, moderate 
quality evidence (1B)
The method of choice for dialysis is CRRT, preferably 
hemodiafiltration. Peritoneal dialysis is a far less effective 
method. Exchange transfusions should be avoided.
Table 4 Medications used in acute management of hyperammonemia and their dosages
Medications Mechanism of action Dosage Route Adverse reaction*
sodium benzoatea Conjugation with glycine 
to form hippuric acid
Weight #20 kg:
250 mg/kg as loading dose 
over 90 minutes followed by 
250–500 mg/kg/day
Weight .20 kg: 5.5 g/m2 as 
loading dose over 90 minutes 
followed by 5.5 g/m2/dayb
iV Cardiovascular: hypotension
Dermatologic: injection site reaction
electrolytes imbalance: hyperglycemia, 
hypokalemia, hypernatremia
gastrointestinal: vomiting, diarrhea
Cns: altered mental status, seizure, 
cerebral edema
Other: fever
sodium phenylacetatea Conjugation with glutamine 
to form phenylacetylglutamine
same as for sodium benzoate iV same as for sodium benzoate
aMMOnUl®c Contains both sodium 
benzoate and sodium 
phenylacetate
same as for sodium benzoate iV (aMMOnUl® 
could be given 
through peripheral 
line on limited basis)
same as for sodium benzoate
l-arginine as an intermediate metabolite 
in the urea cycle. it can 
improve the flow through 
the urea cycle and thereby 
improves ammonia removal
250–400 mg/kg/day as loading 
dose over 90 minutes followed 
by 250–400 mg/kg/day
iV hyperchloremic metabolic alkalosis, 
hypokalemia, elevated BUn and 
creatinine levels, flushing, nausea, 
vomiting, abdominal cramps, bloating, 
numbness, headache
Carbaglu®  
(carglumic acid)d
Replace N-acetylglutamate as 
an activator of mitochondrial 
carbamoyl phosphate 
synthetase, the first enzyme 
of the urea cycle
100 mg/kg bolus per ng 
tube, then 25–62.5 mg/kg 
every 6 hours
ng abdominal pain, diarrhea, vomiting, 
anemia, otitis media, tonsillitis, 
nasopharyngitis, fever, headache
Notes: ait should be given through central line, however, could be given peripherally on limited basis. bIf on hemodialysis/hemodiafiltration, maintenance doses should be 
increased to 350 mg/kg/day (or proportional increase for body surface-based dose calculation). cit is supplied as a vial of 50 ml or 5,000 mg constituted of concentrated, 
aqueous 10% sodium benzoate and 10% sodium phenylacetate solution. Thus, each ml provides 100 mg of sodium benzoate and 100 mg of sodium phenylacetate in water. 
according to the prescribing information, aMMOnUl must be diluted with sterile dextrose injection, 10% at $25 ml/kg before administration. dit is supplied as 200 mg 
tablet; 5 or 60 tablets in a polypropylene bottle with polyethylene cap and desiccant unit. *generally all the drugs are well tolerated and adverse reactions are only relevant 
if dosages are very high.
Abbreviations: BUn, blood urea nitrogen; iV, intravenous; ng, nasogastric; Cns, central nervous system.
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statement #9: strong recommendation, low quality 
evidence (1C)
The line for dialysis should be inserted immediately by 
the most experienced physician (depending on the local 
resources).
statement #10: weak recommendation, low quality 
evidence (2C)
Ammonia scavenger therapy needs to be continued during 
dialysis.
nutrition
The metabolic dietitian should be involved immediately 
after diagnosis of a hyperammonemic patient. Initially, all 
protein intakes must be stopped and high calories (IV) must 
be provided as soon as possible. Additional calories may be 
given by nasogastric (NG) tube using glucose polymers, or 
protein-free formulas (eg, Polycose, Maxijul, or Pro-phree 
formulas) if not contraindicated.
Protein should be reintroduced as soon as ammonia 
level is 80–100 µmol/L to maximize caloric intake and this 
should not be delayed more than 24–48 hours. If there is 
hyperglycemia, start insulin drip and do not decrease the 
rate of dextrose infusion.
statement #11: strong recommendation, low quality 
evidence (1C)
In management of acute hyperammonemia, it is essential to 
achieve high caloric intake by giving IV dextrose 10% or 
higher if appropriate with age-dependent glucose requirement 
and IV lipid emulsion (if a fatty acid oxidation disorder has 
been excluded).
Protein should be reintroduced when ammonia returns 
to 80–100 µmol/L and this should not be delayed more than 
24–48 hours. Protein should be reintroduced after 48 hours 
even if ammonia is still .100 µmol/L.
Practical issues that may arise during 
management of acute hyperammonemia
statement #12:
 1. Ondansetron (0.15 mg/kg) could be given to avoid vomit-
ing when boluses of the ammonia scavengers are given,53 
strong recommendation, low quality evidence (1C).
 2. Laxative: Treat constipation aggressively since ammo-
nia is also produced from urea breakdown by intestinal 
bacteria,54,55 strong recommendation, low quality evi-
dence (1C).
 3. If patient not diagnosed, consider additional administration 
of carnitine 100 mg/kg IV, hydroxycobalamin 1 mg intra-
muscular/intravenous, and biotin 10 mg IV/peroral,17 strong 
recommendation, moderate quality evidence (1B).
 4. Antibiotics: Preferred to continue or initiate them as 
prophylaxis, strong recommendation, low quality evi-
dence (1C).
 5. Hyperventilation: When patient is ventilated, it is rec-
ommended to perform moderate hyperventilation to 
counteract cerebral edema,43 strong recommendation, 
low quality evidence (1C).
 6. Mannitol: It has not been demonstrated to be effective in 
managing cerebral edema caused by hyperammonemia 
and therefore, it should not be given,43 strong recom-
mendation, low quality evidence (1C).
 7. Steroids should be avoided as they increase the amount of 
protein turnover and hence increase the nitrogen load,43 
strong recommendation, low quality evidence (1C).
 8. Glucose and insulin can serve as suppressors of catabolism, 
but their use require care. Consider insulin if hyperglyce-
mia develops (blood glucose level .10 mmol/L) at dose 
of 0.05–0.1 unit/kg/h and titrate up until blood glucose 
controlled. The presence of glycosuria is an indication for 
continued administration of IV regular insulin at a rate that 
keeps glucose levels between 6.5 and 10 mmol/L, weak 
recommendation, low quality evidence (2C).
 9. Valproic acid should be avoided in any patient who 
has known risk for hyperammonemia. It is known to 
decrease urea cycle function by inhibition of N-acetyl-
glutamate synthase,56 strong recommendation, low qual-
ity evidence (1C).
10. NaHCO
3
: Not recommended except if there is refrac-
tory acidosis, weak recommendation, low quality 
evidence (2C).
11. Citrulline: A clear diagnosis should be made before 
supplementing the patient with citrulline. Patients with 
argininosuccinate synthetase and argininosuccinate 
lyase deficiency have elevated citrulline,43 strong rec-
ommendation, moderate quality evidence (1B).
12. If the patient is on combined sodium benzoate and 
phenyl acetate (AMMONUL®) or arginine give KCl 40 
meq/L because they cause hyperchloremic hypokalemic 
metabolic acidosis. KCl can be given through peripheral 
line up to 60 meq/L, rate must not exceed 0.125 meq/kg/h, 
weak recommendation, low quality evidence (2C).
13. KCl can be given in the same line with lipid and ammo-
nia scavengers, weak recommendation, low quality 
evidence (2C).
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14. Combined sodium benzoate and sodium phenylacetate 
(AMMONUL®) can be given through peripheral lines, if 
no central line can be established, strong recommenda-
tion, low quality evidence (1C).
15. Reloading of ammonia scavengers should only be 
considered in neonates with severe hyperammonemic 
decompensation or those who are undergoing dialysis, 
and should be given with great caution to avoid adverse 
effects due to increased serum drug concentrations,43 
strong recommendation, low quality evidence (1C).
Prognosis
Poor prognostic factors in such cases include the 
following:
•	 Hyperammonemic coma has lasted more than 3 days.17,57
•	 Intracranial pressure is clearly increased.17
•	 High level and long duration of hyperammonemia.17
statement #13: strong recommendation, low quality 
evidence (1C)
Neurodevelopmental prognosis is mainly dependent on total 
duration of coma, peak ammonia levels, and number of epi-
sodes of hyperammonemia. Additional studies are needed to 
identify other potential contributing factors.
Conclusion
In summary, there are several challenges and obstacles that 
clinicians face as they try to select the appropriate manage-
ment protocol for acute hyperammonemia. These suggested 
guidelines aim to ease these challenges. However, the rarity 
of these diseases has resulted in mostly low evidence level 
for the statements made here, which corresponds to infer-
ences derived from none analytical studies, such as case 
reports or case series or from expert opinion. Therefore, the 
recommendations contained herein should not be considered 
infallible or absolute.
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